ArticleEMBO molecular medicine2019
Requirement for YAP1 signaling in myxoid liposarcoma.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.Cancer research communications · 2026Article
- Targeting eIF4A-dependent translation in genetically complex sarcoma.JCI insight · 2026Article
- Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma.Science advances · 2025Article
- Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.Biomolecules · 2025Review
- PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization.Frontiers in immunology · 2025Article
- Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.Frontiers in pharmacology · 2025Review
- FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.Biomolecules · 2024Review
- YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer.Annual review of cancer biology · 2024Article
- Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.Cancers · 2024Review
- Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.Frontiers in oncology · 2024Review
- Prognostic value of nuclear morphometry in myxoid liposarcoma.Cancer science · 2023Article
- Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma.Cancers · 2022Review
- On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.International journal of molecular sciences · 2022Review
- Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.Oncogenesis · 2022Article
- FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.Frontiers in oncology · 2022Article
- Retroperitoneal Liposarcoma: An Unusual Presentation of a Rare Cancer.Journal of the advanced practitioner in oncology · 2021Article
- Metabolic landscapes in sarcomas.Journal of hematology & oncology · 2021Review
- Article
- Article
- Sarcoma treatment in the era of molecular medicine.EMBO molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 3 countries.
Marcel TrautmannGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.ORCID 0000-0002-5842-1196
Ya-Yun ChengDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Patrizia JensenDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ninel AzoiteiDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Ines BrunnerDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jennifer HülleinFaculty of Biosciences, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-4421-5260
Mikolaj SlabickiDepartment of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ilka IsfortGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.ORCID 0000-0002-7485-8769
Magdalene CyraGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.ORCID 0000-0001-7738-2703
Ruth BertholdGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.ORCID 0000-0001-7918-1657
Eva WardelmannGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Sebastian HussGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Bianca AltvaterDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.ORCID 0000-0003-4936-4879
Claudia RossigDepartment of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.ORCID 0000-0001-5853-8354
Susanne HafnerInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.
Thomas SimmetInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.
Anders StåhlbergDepartment of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-4243-0191
Pierre ÅmanDepartment of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-1482-8875
Thorsten ZenzDepartment of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-7890-9845
Undine LangeDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.
Thomas KindlerDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.
Claudia SchollGerman Cancer Consortium, Heidelberg (Frankfurt/Mainz), Germany.
Wolfgang HartmannGerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany wolfgang.hartmann@ukmuenster.de stefan.froehling@nct-heidelberg.de.ORCID 0000-0002-7609-5021
Stefan FröhlingDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany wolfgang.hartmann@ukmuenster.de stefan.froehling@nct-heidelberg.de.ORCID 0000-0001-7907-4595
University Hospital Münster · DEGerman Cancer Research Center · DEUniversity Hospital Ulm · DEJohannes Gutenberg University Mainz · DESahlgrenska University Hospital · SEHeidelberg University · DEUniversity of Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin, are driven by the
Indexed as
Signal TransductionAdaptor Proteins, Signal TransducingAnimalsApoptosisCell Line, TumorCell ProliferationCellular SenescenceChickensHEK293 CellsHumansInhibitory Concentration 50Liposarcoma, MyxoidMesenchymal Stem CellsMitosisRNA-Binding Protein FUSRNA InterferenceAdaptor Proteins, Signal TransducingDDIT3 protein, humanRNA-Binding Protein FUSTranscription Factor CHOPTranscription FactorsVerteporfinYAP1 protein, humanYAP-Signaling ProteinsFUS‐DDIT3Hippo pathwaymyxoid liposarcomaverteporfinYAP1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.